Earlier this week, Mizuho highlighted Kinder Morgan's substantial US$9.3 billion project backlog, with US$8.4 billion ...
Arcus Biosciences' estimated fair value is US$41.75 based on 2 Stage Free Cash Flow to Equity Arcus Biosciences is estimated to be 39% undervalued based on current share price of US$25.56 The US$32.22 ...